Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside

J Clin Oncol. 2012 Feb 10;30(5):e64-8. doi: 10.1200/JCO.2011.38.2614. Epub 2011 Dec 27.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzenesulfonates / administration & dosage
  • Bevacizumab
  • Child
  • Child, Preschool
  • Drug Synergism
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Indoles / administration & dosage
  • Male
  • Molecular Targeted Therapy* / methods
  • Neurofibromatosis 2 / drug therapy*
  • Neurofibromatosis 2 / genetics
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / administration & dosage
  • Pyrroles / administration & dosage
  • Quinazolines / administration & dosage
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Sorafenib
  • Sunitinib
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • Treatment Outcome
  • Valproic Acid / administration & dosage
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Quinazolines
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • Valproic Acid
  • temsirolimus
  • Sorafenib
  • Erlotinib Hydrochloride
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sunitinib
  • Sirolimus